Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 112Myeloid 94Sarcoma 18Gastrointestinal 18Lymphoid 16Tumor-Agnostic 8Dermatologic 5Gynecologic 2CNS 2Head & Neck 1Breast 1

Conditions

Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Trastuzumab 728Paclitaxel 694Cyclophosphamide 647Docetaxel 559Capecitabine 485Letrozole 437Fulvestrant 398Carboplatin 397Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 272exemestane 258Epirubicin 251Radiotherapy 239pertuzumab 237palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
nilotinib × Breast × Clear all
NCT04205903 2025-06-29

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
11 enrolled 9 charts
Breast

Anatomic Stage I Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡